NEU — Neuren Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$2.95bn
- AU$2.66bn
- AU$64.63m
Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales
Brief: Neuren Pharmaceuticals Says Co To Get $150M from Acadia Pharma's Pediatric Voucher Sale
Neuren Pharmaceuticals tops benchmark after US partner sells FDA review voucher
Brief: Neuren Pharmaceuticals Says Daybue Receives Marketing Authorization In Canada
Brief: Neuren Pharmaceuticals Posts H1 Net Income AUD 8 Mln
Brief: Neuren Pharmaceuticals Seeks Trading Halt
Brief: Neuren Pharmaceuticals Posts Qtrly Net Sales Of Us$84.6 Mln
Brief: Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From FDA
Aussie healthcare stocks set to log modest gains in first-half 2024
Australia's Neuren Pharmaceuticals slumps 12% on profit-taking after positive drug trial
Australia's Neuren Pharma jump on positive trial results to treat Pitt-Hopkins
Brief: Neuren Pharmaceuticals Seeks Trading Halt
Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee
Brief: Neuren Pharmaceuticals Says Daybue Q1 2024 Net Sales $75.9 Million
Brief: Neuren Pharmaceuticals Says Trofinetide New Drug Submission For Rett Syndrome Accepted For Priority Review By Health Canada
Culper Research discloses short position in Acadia Pharma (updated)
Australian healthcare stocks on track to end 2023 higher
Brief: Neuren Says Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Australia's Neuren Pharmaceuticals hits record high on successful drug trial